

SUPPLEMENTARY APPENDIX


Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Pooled Results From Two Randomized Phase 3 Studies

Lawrence F. Eichenfield, MD, Eric L. Simpson, MD, MCR, Kim Papp, MD, PhD, Jacek C. Szepietowski, MD, PhD, FRCP (Edin), Andrew Blauvelt, MD, MBA, Leon Kircik, MD, Jonathan I. Silverberg, MD, PhD, MPH, Elaine C. Siegfried, MD, Michael E. Kuligowski, MD, PhD, MBA, May E. Venturanza, MD, Howard Kallender, PhD, Haobo Ren, PhD, Amy S. Paller, MD

CONTENTS


Figure S1. Percentage of Patients Achieving (A) a ≥ 6-Point Improvement in PROMIS 8a Score and (B) a ≥ 6-Point Improvement in PROMIS 8b Score Throughout the VC Period.....	Pg 2
Figure S2. Itch Responses per POEM Q1.....	Pg 3
Figure S3. Mean Change From Baseline in CDLQI.....	Pg 4
Table S1. Exposure-Adjusted TEAEs Among Adolescents Who Continued Into the LTS Period.....	Pg 5

Figure S1. Percentage of Patients Achieving (A) a ≥ 6 -Point Improvement in PROMIS 8a Score and (B) a ≥ 6 -Point Improvement in PROMIS 8b Score Throughout the VC Period.




PROMIS 8a, Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment Score; PROMIS 8b, Patient-Reported Outcomes Measurement Information System Sleep Disturbance Score; VC, vehicle controlled. [†] Patients with missing postbaseline values were imputed as non-responders at Weeks 2, 4, and 8. [‡] Defined as a ≥ 6 -point improvement in PROMIS 8a/8b. Patients in the analysis had a PROMIS 8a/8b score of ≥ 6 at baseline.

Figure S2. Itch Responses per POEM Q1.



BL, baseline; POEM Q1, question 1 of the Patient Oriented Eczema Measure.

Figure S3. Mean Change From Baseline in CDLQI.



BL, baseline; CDLQI, Children's Dermatology Life Quality Index.

** $P < 0.01$ vs. vehicle. **** $P < 0.0001$ vs. vehicle.

Table S1. Exposure-Adjusted TEAEs Among Adolescents Who Continued Into the LTS Period

Characteristic, n (exposure-adjusted IR per 100 PY)	Vehicle* (n=45)	1.5% Ruxolitinib Cream† (n=114)
Patients with TEAE‡	17 (256.7)	60 (66.8)
Patients with TRAE	5 (75.5)	5 (5.6)
Patients with serious TEAE	0	0
Patients who discontinued due to a TEAE	0	0
Patients with application site reactions	4 (60.4)	2 (2.2)

IR, incidence rate; PY, patient-year; TEAE, treatment-emergent adverse event.

* Patients in the vehicle group applied vehicle for 8 weeks during the vehicle-controlled period; data in this table are adjusted for exposure.

† Patients in the 1.5% ruxolitinib cream group had up to 52 weeks of exposure depending on whether they were initially randomized to 1.5% ruxolitinib cream in the vehicle-controlled period or switched from vehicle to 1.5% ruxolitinib cream at the start of the long-term safety period; data in this table are adjusted for exposure.